An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui‐Ru Ji(Bristol-Myers Squibb (United States)), Scott D. Chasalow(Bristol-Myers Squibb (United States)), Lisu Wang(Bristol-Myers Squibb (United States)), Omid Hamid(Angeles Clinic and Research Institute), Henrik Schmidt(Aarhus University Hospital), John Cogswell(Bristol-Myers Squibb (United States)), Suresh Alaparthy(Bristol-Myers Squibb (United States)), David M. Berman(Bristol-Myers Squibb (United States)), Maria Jure–Kunkel(Bristol-Myers Squibb (United States)), Nathan O. Siemers(Bristol-Myers Squibb (United States)), Jeffrey R. Jackson(Bristol-Myers Squibb (United States)), Vafa Shahabi(Bristol-Myers Squibb (United States))
Cancer Immunology Immunotherapy
December 6, 2011
10.1007/s00262-011-1172-6
Cited by 777Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis